BLCO — Bausch + Lomb Corporation Company Overview

Executive Summary

Bausch + Lomb Corporation (NYSE: BLCO), founded in 1853, is a fully integrated global eye health company operating in roughly 100 countries with approximately 13,000 employees and a portfolio of about 400 products spanning consumer eye care, contact lenses, pharmaceuticals, and ophthalmic surgical devices. The company completed its IPO in May 2022 as a partial carve-out from Bausch Health Companies Inc. (BHC), which as of the company's most recent annual report continued to hold approximately 88% of shares outstanding, with a full separation still a stated long-term intention rather than a completed fact. For fiscal 2025, total segment revenue was approximately $5.1 billion, split across three reporting segments: Vision Care, Pharmaceuticals, and Surgical.

Core Business Model

Bausch + Lomb manufactures and markets eye health products across three distinct commercial motions: a consumer/retail business selling vitamins, lubricating drops, and contact lenses direct to consumers and through eye-care professionals (ECPs); a specialty pharmaceutical business selling prescription ophthalmic drugs through ECPs and pharmacy channels; and a medical device business selling intraocular lenses and surgical capital equipment/consumables into hospitals and ambulatory surgery centers. The integrated model — spanning the full continuum from everyday consumer eye care to complex cataract and vitreoretinal surgery — is a deliberate strategy to deepen relationships with ECPs who influence or make purchase decisions across multiple product categories.

Business Segments

Vision Care is the largest segment at 57% of fiscal 2025 revenue ($2,923 million), encompassing consumer eye vitamins and supplements (PreserVision, Ocuvite), lubricating and allergy/redness-relief drops (Blink, Artelac), and the contact lens business spanning daily disposable, planned-replacement, and specialty lenses under brands including Bausch + Lomb ULTRA and Biotrue. Pharmaceuticals is the smallest segment by revenue at 25% ($1,284 million) but is strategically the most important growth and margin driver, anchored by Xiidra (dry eye disease, acquired in 2023) and Miebo (launched in the U.S. in September 2023), alongside Vyzulta, Lotemax, and Prolensa for glaucoma, inflammation, and post-surgical indications. Surgical contributed 18% of revenue ($894 million), covering intraocular lenses (the enVista platform) and surgical capital equipment such as the Stellaris Elite phacoemulsification system and the VICTUS femtosecond laser platform used in cataract and refractive procedures.

Product Portfolio

Flagship brands include PreserVision and Ocuvite (AREDS2-formula eye vitamins), Biotrue and Bausch + Lomb ULTRA (contact lenses), Blink and Artelac (lubricating drops), Xiidra and Miebo (prescription dry eye therapies), Vyzulta and Lotemax (glaucoma and inflammation), and enVista, Stellaris Elite, and VICTUS (surgical devices and IOLs). This breadth allows Bausch + Lomb to be present at nearly every point of contact an eye-care professional or patient has with the eye health system, from an annual vitamin purchase to a cataract surgery.

Competitive Landscape

Bausch + Lomb faces different, and in most cases larger, competitors in each segment. In contact lenses and consumer vision care, it competes against Johnson & Johnson Vision (Acuvue), Alcon, and CooperVision (a division of The Cooper Companies) — all of which have greater scale in at least some sub-categories. In ophthalmic surgical devices and IOLs, its principal rivals are Alcon, the largest pure-play eye care company globally, and Carl Zeiss Meditec, both of which have deep installed bases of surgical equipment that create their own switching-cost dynamics favoring incumbents. In pharmaceuticals, Bausch + Lomb's branded dry-eye and glaucoma therapies compete against other specialty ophthalmic drug makers and, over time, face the risk of generic erosion as patents mature. Across every segment, Bausch + Lomb is generally a smaller, less-capitalized player relative to Alcon in particular, making execution and innovation critical to maintaining share.

Strategic Strengths & Risks

The company's core strength is its 170-plus-year brand, which carries deep trust with both consumers and eye-care professionals and supports premium positioning even in commoditized categories like OTC vitamins. The fully integrated model across consumer, pharma, and surgical creates cross-selling opportunities with ECPs that narrower competitors cannot replicate, and recent pharmaceutical launches (Miebo, the Xiidra acquisition) have added higher-margin, patent-protected revenue that diversifies the business away from more commoditized contact lens and vitamin categories.

The most significant risk specific to Bausch + Lomb is its ownership structure: continued majority ownership by the heavily leveraged Bausch Health Companies creates a persistent capital-allocation and strategic overhang, and the timeline for a full, clean separation remains uncertain. Competitively, the company is a mid-sized player against much larger, better-resourced rivals (particularly Alcon and J&J Vision) in categories where R&D scale and manufacturing footprint matter. Its pharmaceutical assets, while higher-margin, are also exposed to eventual patent expiration and generic competition. The business carries meaningful foreign-exchange exposure given its roughly 100-country footprint, and its consumer and contact lens categories in particular are subject to ongoing price competition that limits overall pricing power despite brand strength.

Financial Overview

Fiscal 2025 revenue totaled approximately $5.1 billion across the three segments, with Vision Care as the largest but likely lowest-margin contributor, Pharmaceuticals the smallest but fastest-growing and highest-margin segment on the strength of Xiidra and Miebo, and Surgical providing a mid-sized, capital-equipment-driven revenue stream with its own recurring consumables tail (IOLs, disposables used with Stellaris Elite and VICTUS). The company continues to operate with leverage tied to its relationship with parent Bausch Health, and its capital structure and strategic direction remain influenced by BHC's own financial situation pending any further separation steps.

Summary Conclusion

Bausch + Lomb combines a genuinely durable global brand and an unusually complete eye-health product continuum with real competitive intensity from larger rivals in every segment it serves. The moat here is moderate: strong in brand trust, ECP relationships, and patent-protected pharmaceutical assets, but constrained by commoditized categories (contact lenses, OTC vitamins) with limited pricing power and by the unresolved overhang of majority ownership by a highly leveraged parent company.